Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Urso

Dermatology Spokane, WA Medical Doctor

NPI 1427545433 CMS profile 11254682

510 S Cowley St Ste 200, Spokane, WA 99202

Open in the dashboard

General payments

$5,133

214 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Urso of Spokane, WA is reported in the CMS Open Payments database as having received $5,133 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,544 76
2024 General $1,995 80
2023 General $1,156 44
2022 General $338 13
2021 General $100 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Urso
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Brittany Urso were reported at $1,544. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Brittany Urso Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $100 $377 $108–$1,108 $132
2022 $338 $514 $143–$1,391 $149
2023 $1,156 $607 $159–$1,674 $160
2024 $1,995 $751 $204–$1,903 $164
2025 $1,544 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,062 40 payments
  2. Lilly USA, LLC $830 33 payments
  3. Janssen Biotech, Inc. $778 32 payments
  4. Regeneron Healthcare Solutions, Inc. $479 16 payments
  5. Genzyme Corporation $338 10 payments
  6. Galderma Laboratories, L.P. $304 15 payments
  7. UCB, Inc. $292 19 payments
  8. Incyte Corporation $179 9 payments
  9. E.R. Squibb & Sons, L.L.C. $150 10 payments
  10. Dermavant Sciences, Inc. $110 6 payments
  11. Other $612 24 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,665 209 payments
  2. Education $468 5 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $653 24 payments
  2. TALTZ $634 28 payments
  3. DUPIXENT Immunology $488 13 payments
  4. OLUMIANT $379 14 payments
  5. DUPIXENT Inflammation And Immunology $350 11 payments
  6. BOTOX $272 9 payments
  7. Bimzelx $247 17 payments
  8. SKYRIZI $240 11 payments
  9. RINVOQ $200 11 payments
  10. EBGLYSS $196 10 payments
  11. Other $2,109 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

608

Median for Dermatology: 534

Drug cost

$194,567

Median for Dermatology: $67,151

Branded share of claims

10.2%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 24 $88,007
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $87,439
Clobetasol Propionate Generic 75 $3,236
Azelaic Acid Generic 29 $3,086
Tacrolimus Generic 15 $2,687
Ketoconazole Generic 94 $2,020
Zenatane Isotretinoin Brand 12 $1,439
Metronidazole Generic 25 $1,069
Triamcinolone Acetonide Generic 59 $1,009
Ciclopirox Generic 32 $857

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$106,979

Of which drugs: $3,426

Medicare patients

436

Average age 75

Services billed

2,396

276 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 52%
Arthritis 44%
Diabetes 17%
Osteoporosis 16%
Ischemic heart disease 15%
Chronic kidney disease 15%
Depression 15%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 39 $29

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $281
  • GENZYME CORPORATION $118
$399 24 —
SKYRIZI
  • AbbVie, Inc. $185
$185 — —
BOTOX
  • AbbVie, Inc. $178
$178 — —
TREMFYA
  • Janssen Biotech, Inc. $143
$143 — —
TALTZ
  • Lilly USA, LLC $133
$133 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record